This work found that MOBT blocked MEF2c alternative splicing to prevent pulmonary fibrosis by reducing the formation of the lncITPF–hnRNP L complex, and that the lncITPF–hnRNP L could be a therapeutic drug target in pulmonary fibrosis. The gene discussed is HNRNPL; the disease is pulmonary fibrosis.